ClinicalTrials.gg
Enrolling by invitationNCT04326426Updated Apr 20, 2020

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

A Phase 3 interventional study of Tradipitant and Placebo in Coronavirus Infection, sponsored by Vanda Pharmaceuticals. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2020, 6 years 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 401 studies in Coronavirus Infections with a site in United States — 30 open to participants now, 40 under way, 7 of them phase 3. Coronavirus Infections · United States.

Planned enrollment
86th of 283
300 · median 94
Started
2020
with 251 others
Phase 3
52 of 401
7 open now
Primary completion
2020-08
later than 0 of 38 live
Registered
34th of 401
by date

Among the 401 studies in Coronavirus Infections with a site in United States, this one is the 86th largest by planned enrollment of the 283 interventional ones that give a count, is one of 252 that started in 2020, is one of 52 in phase 3, reaches primary completion later than 0 of the 38 other live ones, and was the 34th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

30 of the 401 studies in Coronavirus Infections with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Coronavirus Infections with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection.

On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.

03

Conditions studied

  • Coronavirus Infection
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-90
  • Confirmed laboratory COVID-19 infection by RT-PCR
  • Meeting severe or critical criteria of COVID-19 infection as defined at treating hospital
  • Confirmed pneumonia by chest radiograph or computed tomography
  • Fever defined as temperature ≥ 36.6 °C armpit, ≥ 37.2 °C oral, or ≥ 37.8 °C rectal
  • Oxygen saturation less than 92%

Exclusion criteria

Exclusion Criteria:

  • Recent use of illicit drugs or alcohol abuse
  • Known allergy to tradipitant or other neurokinin-1 antagonists
  • Pregnancy
  • Known , , or infection
  • Malignant tumor, other serious systemic diseases
  • Inability to provide or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Tradipitant

    Tradipitant 85 mg PO BID

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    2 capsules of matching placebo

    Drug: Placebo

Interventions

  • Neurokinin-1 antagonist

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Time to improvement on a 7-point ordinal scale as compared to baseline

    Time frame: 14 days or discharge

Secondary outcomes

  1. Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)

    Time frame: 14 days or discharge

  2. Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples

    Time frame: 14 days or discharge

  3. In-hospital mortality

    Time frame: 14 days or discharge

  4. Mean change in NEWS2 score from baseline

    Time frame: 14 days or discharge

  5. Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus

    Time frame: 14 days or discharge

  6. Reduction from baseline of NRS for cough

    Time frame: 14 days or discharge

  7. Reduction from baseline of NRS for nausea

    Time frame: 14 days or discharge

  8. Time to normalization of fever for at least 48 hours

    Time frame: 14 days or discharge

  9. Time to improvement in oxygenation for at least 48 hours

    Time frame: 14 days or discharge

07

Study locations

1 site
08

References and documents

Publications

  • Smieszek SP, Przychodzen BP, Polymeropoulos VM, Polymeropoulos CM, Polymeropoulos MH. Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients'. Cytokine. 2021 Dec;148:155662. doi: 10.1016/j.cyto.2021.155662. Epub 2021 Jul 29. Erratum In: Cytokine. 2022 Jan;149:155752. doi: 10.1016/j.cyto.2021.155752. PubMed 34353696 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Aug 2020, 3 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Coronavirus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 25. This study's planned 3 months is below that.

Counting every sponsor, half of 91 studies reached it within 11 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Mar 30, 2020
StartActual
Apr 13, 2020
Primary completionEst.
Aug 1, 2020
CompletionEst.
Aug 31, 2020
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04326426
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
Apr 13, 2020
Primary completion
Aug 1, 2020 (estimated)
Completion
Aug 31, 2020 (estimated)
Last update
Apr 20, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion